News

Video

AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections

Key Takeaways

  • Chloroprocaine ophthalmic gel provides effective anesthesia for intravitreal injections, initially approved for cataract surgery.
  • Studies show the gel, combined with betadine, removes more bacterial colonies than tetracaine drops, reducing endophthalmitis risk.
SHOW MORE

Michael Singer, MD, shared insights from his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

Michael Singer, MD, shared insights on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

This transcript has been lightly edited for clarity.

Michael Singer, MD: Hi, my name is Michael Singer. I'm thrilled today to talk about Iheezo. Basically what it is, it's a topical anesthetic. It's a viscous anesthetic, and initially it was approved for the use in cataract surgery, but recently its transition for the use is prep for patients who want anesthesia in intravitreal injections, and I've been incorporating it into my practice over the last 5 to 6 months and had very good success.

What I think is interesting to understand on this gel, because when I talk to a lot of my colleagues, they're all worried about gels have a fairly bad reputation, because they say there's an increase in endophthalmitis versus topical liquid juice for anesthesia. Well, it turns out recently, there was a study that looked at the use of betadine in conjunction with the gel, as opposed to using it in conjunction with tetracaine drops. And what it showed was that more colonies were removed using betadine with the gel than with the drops, basically explaining that this is even safer than tetracaine drops. So what I love about the concept is we're dispelling a myth. We're able to give better anesthesia for our patients and actually inject them more efficiently to make the whole experience for both them and for us, more beneficial. I mean, in my experience, it has basically been at least as quick, if not quicker, than typical tetracaine-based gels.

It was shown during the cataract surgery process that essentially within 90 seconds you're able to get anesthesia, and they ran a number of studies that showed, over time, at 3 different time points that that you, with 3 installations, 90 seconds later, you were able to do cataract surgery without needing any supplemental anesthesia, which was really important because the tetracaine dropped arm needed supplemental anesthesia while the Iheezo did not Well, obviously I made reference to this earlier. The thing that basically keeps us up at night is endophthalmitis. And the story is that, the fallacy or wasn't a fallacy, it was at least a myth that patients who had gels were more likely to end up with endophthalmitis after intravitreal injections and cataract surgeries than patients who had drops. The study there, where we showed that there were less colony forming bacteria with the use of Iheezo in conjunction with betadine, as opposed to Iheezo in conjunction with tetracaine drops. Adds a lot of credibility to the fact that this is a good, safe alternative to our patients undergoing intraocular procedures, whether it be a cataract or intravitreal injections.

Well, one of the things that patients have problems with is they maybe have sensitivity to summon a preservative things, things like the AK and other things of that nature. Having a preservative-free formulation is one less thing we have to worry about so our patients don't have postoperative pain, and they have a suboptimal postoperative experience, and our staff is called the hours in the evening and on weekends because they don't feel it. It's one less thing to worry about, just like we do with our drops.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.